RxDoctor Payments Data

Matthew Gewirtz, MD

Ophthalmology · Warren, NJNPI 1417909771

Payments from drug & device makers

$3,008in general payments, 2019–2025

Across 52 payments — averaging $57.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$2K
  • Johnson & Johnson Surgical Vision, Inc.$448
  • AbbVie$354
  • Sight Sciences, Inc.$140
  • Dompe US, Inc.$70
  • Rxsight Inc$70
  • plus $197 from 9 others

What the payments were for

  • Food & beverage$3,008100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,008 in reported general payments places this provider in the 65th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,037,309
Medicare patients
794
Services billed
11,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost103$47,970
RestasisCyclosporine40$38,387
TyrvayaVarenicline Tartrate28$22,054
XiidraLifitegrast12$14,172
Prednisolone Acetate320$12,445
ProlensaBromfenac Sodium32$11,353
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$8,815
Brimonidine Tartrate98$8,202
CombiganBrimonidine Tartrate/Timolol28$7,103
Bromfenac Sodium32$6,337
Travoprost26$6,284
Latanoprost366$4,916
Timolol Maleate164$4,425
Tobramycin-DexamethasoneTobramycin/Dexamethasone99$3,481
Ciprofloxacin Hcl263$2,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$354$93,460171 claims
Oyster Point Pharma, Inc.Tyrvaya$21$22,05428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Warren

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →